GANX · Gain Therapeutics, Inc.
$1.66
+0.05 (+2.79%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”View the 10-Q filed Aug 11, 2026
Market Cap
$71.58M
Shares
43.64M
Volume · Oct 9
328.7K
Avg daily vol (3M)
495.89K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.62
Open$1.66
Day$1.61–1.68
52W close$1.59–4.18
Avg vol 30d420K
Short int3.1M · 7.0% float · 5.9d
Short vol80%
Last earningsMar 23, 2026
DataMar 2021–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$20.11M
Trailing 12 months
Revenue growth YoY
+22.6%
Year over year
Operating margin
-40,328.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+41.3%
Year over year · more shares
Price change (1Y)
-17.3%
Trailing year
Short interest
7.0%
Latest settlement · 5.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−12%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−24%
trailing
YTD return
−50%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
1 of 50 funds reported for Sep 30 · net -21.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.00% of float · ▲ +5.9% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
−61%
Y/Y
EPS growth
+31%
Y/Y
Free cash flow
$-18.6M
Balance sheet
$20.4M
net cash
Quant / Vol
risk profile
Volatility
107%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
1 of 50 funds reported for Sep 30 · net -21.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.00% of float · ▲ +5.9% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 1%
Range high $4
vs 200-day avg -18%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GANX
this stock
Gain Therapeutics, Inc.
|
$71.58M | -49.8% | -60.6% | — | 7.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GANX | -6.1% | -5.6% | -24.2% | -6.7% | -49.8% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -7.4% | -7.7% | -33.2% | -8.1% | -63.3% |